{"groups":[{"description":"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)\n\nYou will receive 1 dose of Outpatient IV at Bevacizumab 7.5mg/kg.\n\nHD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC\n\nGemcitabine: 1800 mg/m\\^2 IV over 3 hours on Days -5 to Day -2.\n\nDocetaxel: Docetaxel 300 mg/m\\^2 IV over 2 hours on Day -5.\n\nMelphalan: 50 mg/m\\^2 IV over 15 minutes on Days -4 to Day -2.\n\nCarboplatin: Cycle 1: 333 mg/m\\^2 IV over 2 hours on Days -4 to -2.\n\nStem Cell Transplant: Stem cell infusion on Day 0.\n\nSecond Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)\n\nHD Cycle #2: Ifosfamide/Carboplatin/Etoposide (ICE) + PBPC\n\nCarboplatin: Cycle 1: 333 mg/m\\^2 IV over 2 hours on Days -4 to -2.\n\nCycle #2: 300 mg/m\\^2 IV over 2 hours on Days -6 to -3.\n\nMesna: 3,000 mg/m\\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.\n\nIfosfamide: 3,000 mg/m\\^2 IV over 6 hours on Days -6 to -3\n\nEtoposide: 200 mg/m\\^2 IV over 3 hours, every 12 hours on Days -6 to -4.\n\nStem Cell Transplant: Stem cell infusion on Day 0.","id":"FG000","title":"Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT"},{"description":"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)\n\nHD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC\n\nGemcitabine: 1800 mg/m\\^2 IV over 3 hours on Days -5 to Day -2.\n\nDocetaxel: Docetaxel 300 mg/m\\^2 IV over 2 hours on Day -5.\n\nMelphalan: 50 mg/m\\^2 IV over 15 minutes on Days -4 to Day -2.\n\nCarboplatin: Cycle 1: 333 mg/m\\^2 IV over 2 hours on Days -4 to -2.\n\nStem Cell Transplant: Stem cell infusion on Day 0.\n\nSecond Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)\n\nHD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC\n\nCarboplatin: Cycle 1: 333 mg/m\\^2 IV over 2 hours on Days -4 to -2.\n\nCycle #2: 300 mg/m\\^2 IV over 2 hours on Days -6 to -3.\n\nMesna: 3,000 mg/m\\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.\n\nIfosfamide: 3,000 mg/m\\^2 IV over 6 hours on Days -6 to -3\n\nEtoposide: 200 mg/m\\^2 IV over 3 hours, every 12 hours on Days -6 to -4.\n\nStem Cell Transplant: Stem cell infusion on Day 0.","id":"FG001","title":"Cohort 2: HD GeM-DMC+ ICE for Refractory GCT"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}],"type":"Unrelated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"23"}],"type":"Cycle 1"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"23"}],"type":"Cycle 2"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"All participants were registered in MD Anderson Cancer Center."}